source
- Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savingsThe White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
- CellCentric secures $220 million Series D to advance multiple myeloma oral therapyCellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…